Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. more
Time Frame | ABCL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.62% | -3.39% | 0.2% |
1-Month Return | 5.28% | -1.92% | 2.72% |
3-Month Return | 2.2% | -10.54% | 7.31% |
6-Month Return | -8.82% | -4.47% | 10.44% |
1-Year Return | -47.56% | 4.06% | 27.53% |
3-Year Return | -81.38% | 0.94% | 30.88% |
5-Year Return | -95.26% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 11.61M | 233.16M | 11.61M | 485.42M | 38.02M | [{"date":"2019-12-31","value":2.39,"profit":true},{"date":"2020-12-31","value":48.03,"profit":true},{"date":"2021-12-31","value":2.39,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.83,"profit":true}] |
Cost of Revenue | 10.11M | 27.14M | 45.52M | 66.44M | 30.89M | [{"date":"2019-12-31","value":15.22,"profit":true},{"date":"2020-12-31","value":40.86,"profit":true},{"date":"2021-12-31","value":68.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.5,"profit":true}] |
Gross Profit | 1.50M | 206.01M | 11.61M | 418.99M | 38.02M | [{"date":"2019-12-31","value":0.36,"profit":true},{"date":"2020-12-31","value":49.17,"profit":true},{"date":"2021-12-31","value":2.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.08,"profit":true}] |
Gross Margin | 12.91% | 88.36% | 100.00% | 86.31% | 100.00% | [{"date":"2019-12-31","value":12.91,"profit":true},{"date":"2020-12-31","value":88.36,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 13.95M | 41.66M | 13.95M | 191.92M | 275.23M | [{"date":"2019-12-31","value":5.07,"profit":true},{"date":"2020-12-31","value":15.14,"profit":true},{"date":"2021-12-31","value":5.07,"profit":true},{"date":"2022-12-31","value":69.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (4.12M) | 156.03M | (4.12M) | 216.51M | (237.21M) | [{"date":"2019-12-31","value":-1.9,"profit":false},{"date":"2020-12-31","value":72.07,"profit":true},{"date":"2021-12-31","value":-1.9,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-109.56,"profit":false}] |
Total Non-Operating Income/Expense | 1.85M | (4.42M) | 11.31K | 34.62M | 105.42M | [{"date":"2019-12-31","value":1.76,"profit":true},{"date":"2020-12-31","value":-4.19,"profit":false},{"date":"2021-12-31","value":0.01,"profit":true},{"date":"2022-12-31","value":32.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (2.21M) | 157.83M | (2.21M) | 239.10M | (174.03M) | [{"date":"2019-12-31","value":-0.92,"profit":false},{"date":"2020-12-31","value":66.01,"profit":true},{"date":"2021-12-31","value":-0.92,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-72.79,"profit":false}] |
Income Taxes | 209.20K | 38.91M | 65.69M | 80.58M | (27.63M) | [{"date":"2019-12-31","value":0.26,"profit":true},{"date":"2020-12-31","value":48.29,"profit":true},{"date":"2021-12-31","value":81.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-34.29,"profit":false}] |
Income After Taxes | (2.42M) | 118.92M | (67.90M) | 158.52M | (146.40M) | [{"date":"2019-12-31","value":-1.53,"profit":false},{"date":"2020-12-31","value":75.02,"profit":true},{"date":"2021-12-31","value":-42.83,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-92.35,"profit":false}] |
Income From Continuous Operations | (2.21M) | 118.92M | 153.46M | 158.52M | (146.40M) | [{"date":"2019-12-31","value":-1.39,"profit":false},{"date":"2020-12-31","value":75.02,"profit":true},{"date":"2021-12-31","value":96.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-92.35,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (2.42M) | 118.92M | (2.21M) | 158.52M | (146.40M) | [{"date":"2019-12-31","value":-1.53,"profit":false},{"date":"2020-12-31","value":75.02,"profit":true},{"date":"2021-12-31","value":-1.39,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-92.35,"profit":false}] |
EPS (Diluted) | (0.00) | 0.40 | 0.47 | 0.50 | (0.52) | [{"date":"2019-12-31","value":-0.48,"profit":false},{"date":"2020-12-31","value":79.36,"profit":true},{"date":"2021-12-31","value":94,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-104,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ABCL | |
---|---|
Cash Ratio | 8.08 |
Current Ratio | 9.34 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ABCL | |
---|---|
ROA (LTM) | -13.26% |
ROE (LTM) | -15.55% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ABCL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.23 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.77 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ABCL | |
---|---|
Trailing PE | NM |
Forward PE | 27.47 |
P/S (TTM) | 25.63 |
P/B | 0.78 |
Price/FCF | NM |
EV/R | 8.28 |
EV/Ebitda | 5.30 |
Abcellera Biologics Inc (ABCL) share price today is $2.825
Yes, Indians can buy shares of Abcellera Biologics Inc (ABCL) on Vested. To buy Abcellera Biologics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABCL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Abcellera Biologics Inc (ABCL) via the Vested app. You can start investing in Abcellera Biologics Inc (ABCL) with a minimum investment of $1.
You can invest in shares of Abcellera Biologics Inc (ABCL) via Vested in three simple steps:
The 52-week high price of Abcellera Biologics Inc (ABCL) is $6.05. The 52-week low price of Abcellera Biologics Inc (ABCL) is $2.33.
The price-to-earnings (P/E) ratio of Abcellera Biologics Inc (ABCL) is
The price-to-book (P/B) ratio of Abcellera Biologics Inc (ABCL) is 0.78
The dividend yield of Abcellera Biologics Inc (ABCL) is 0.00%
The market capitalization of Abcellera Biologics Inc (ABCL) is $844.75M
The stock symbol (or ticker) of Abcellera Biologics Inc is ABCL